PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Chart, page-3515

  1. 753 Posts.
    lightbulb Created with Sketch. 138
    There is no way that their current cash on hand will last for most of the current trials, as quoted I the Lodge Partners report.
    If PAR don't get a JV partner, they'll be raising more cash by the end of this year.
    I think Lodge are a little optimistic with their timelines, especially with last patient receiving treatment by end of June (enrolment doesn't equate to a subject receiving treatment).

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.